Riskpilot← Back to searchSign inGet full accessValapharma AB
ABActiveOrg 5566663612Ängsgårdarna 10General medical practice activities · NACE 8621Est. 20040 employees
Revenue 2025
SEK 736K
+18% vs 2024
EBITDA margin
4.2%
-76% vs 2024
Equity ratio
69.6%
Financial strength
Net profit 2025
SEK 2K
+100% vs 2024
| Revenue | SEK 736K | +18% |
| EBITDA | SEK 31K | -76% |
| Net profit | SEK 2K | +100% |
| Total assets | SEK 3,4M | +2% |
| Equity | SEK 2,3M | +0% |
| Employees | 0 | — |
Legal name
Valapharma AB
Org number
5566663612
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
15 september 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva konstnärlig verksamhet, design och life science samt idka därmed förenlig verksamhet.
Address
Ängsgårdarna 10
Email
contact@henrikheino.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 499 | 421 | 624 | 736 |
| Staff expenses | — | — | −774 | −99 | −215 |
| EBITDA | −735 | −60 | −960 | 130 | 31 |
| Depreciation & amort. | −49 | −62 | −60 | −210 | −183 |
| EBIT | −784 | −122 | −1 020 | −80 | −152 |
| Net financials | 606 | 341 | 1 738 | −1 213 | −15 |
| Profit before tax | −179 | 219 | 543 | −1 293 | 8 |
| Tax | −0 | −113 | −112 | 136 | −6 |
| Net profit | −179 | 106 | 432 | −1 157 | 2 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 574 | 3 693 | 4 337 | 3 313 | 3 374 |
| Equity | 2 967 | 3 073 | 3 505 | 2 348 | 2 349 |
| Long-term debt | 552 | 582 | 366 | 0 | — |
| Short-term debt | 55 | 38 | 292 | 790 | 1 025 |
| Total debt | 607 | 620 | 657 | 790 | 1 025 |
EBITDA margin
4.2%
This company
15.8%
Market median
-73% vs market
20212025
Equity ratio
69.6%
This company
38.2%
Market median
+82% vs market
20212025
Return on equity
0.1%
This company
18.4%
Market median
-99% vs market
20212025
Net profit margin
0.3%
This company
8.1%
Market median
-96% vs market
20212025
Asset turnover
0.22×
This company
1.12×
Market median
-80% vs market
20212025
Debt / equity
0.44×
This company
0.62×
Market median
+29% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
CM Audit | Audit | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Valapharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claes Mikael Jennel | Audit | 0 companies |
| Henrik Raimo Grathwohl-Heino | Board of Directors | 0 companies |
| Anna-Karin Olsson Heino | Deputy Board Member | 0 companies |